INAMRINONE

First approved in 1984

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H9N3O
Molecular Weight	187.198
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=CC(=CNC1=O)C2=CC=NC=C2

InChI

InChIKey=RNLQIBCLLYYYFJ-UHFFFAOYSA-N

InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)

HIDE SMILES / InChI

Molecular Formula	C10H9N3O
Molecular Weight	187.198
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01427
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/inamrinone.html

Inamrinone (Amrinone) is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. Inamrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect. Inamrinone is used in the treatment of congestive heart failure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 3A 7 Target ID: CHEMBL241 Sources: http://www.drugbank.ca/drugs/DB01427	Inhibitor 8228	16.7 µM [IC50]
Phosphodiesterase 3B 8 Target ID: CHEMBL290 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10644042	Inhibitor 8228	31.2 µM [IC50]
platelet aggregation 75 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698653	Inhibitor 8228	61.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Congestive heart failure 54 Sources: https://www.drugs.com/pro/inamrinone.html	Primary		Approved 8360	AMRINONE LACTATE Approved Use For the short-term management of congestive heart failure. Launch Date 9.5774402E11

C_max

Value	Dose	Co-administered	Analyte	Population
5.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
245 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Cardiac arrest... Other AEs: Cardiac arrest Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Death... Other AEs: Death (grade 5) Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	Disc. AE: Pulmonary edema, Cardiac arrest... AEs leading to discontinuation/dose reduction: Pulmonary edema Cardiac arrest Respiratory distress syndrome Chest pain Palpitations Ventricular ectopic beats Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	Disc. AE: Diarrhea, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Diarrhea Thrombocytopenia Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
5.8 mg/kg/day 1 times / day multiple, intravenous (mean) Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) n = 43 Health Status: unhealthy Condition: congestive heart failure Age Group: 59.4 (37-81) Sex: M+F Population Size: 43 Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (18.6%) Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456
3 mg/kg 1 times / day single, intravenous (max) Recommended Dose: 3 mg/kg, 1 times / day Route: intravenous Route: single Dose: 3 mg/kg, 1 times / day Sources: https://www.nature.com/articles/pr1984440	unhealthy, <1 n = 6 Health Status: unhealthy Condition: pulmonary hypertension Age Group: <1 Sex: M+F Population Size: 6 Sources: https://www.nature.com/articles/pr1984440	Sources: https://www.nature.com/articles/pr1984440

AEs

AE	Significance	Dose	Population
Cardiac arrest		198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Death	grade 5	198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Cardiac arrest	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Chest pain	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Palpitations	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Pulmonary edema	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Respiratory distress syndrome	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Ventricular ectopic beats	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Diarrhea	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	18.6% Disc. AE	5.8 mg/kg/day 1 times / day multiple, intravenous (mean) Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) n = 43 Health Status: unhealthy Condition: congestive heart failure Age Group: 59.4 (37-81) Sex: M+F Population Size: 43 Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0633	http://www.3bsc.com/index/pro_info.php?id=19989
3B Scientific (Wuhan) Corp	3B1-00216	http://www.3bsc.com/index/pro_info.php?id=20428
AEchem Scientific Corp., USA	AE044729	http://www.aechemsc.com/info_products/AE044729.php
AHH Chemical co.,ltd	API-1603	http://www.ahhchemical.com/product/API-1603.html
AHH Chemical co.,ltd	MT-00030	http://www.ahhchemical.com/product/MT-00030.html
AK Scientific, Inc. (AKSCI)	868269	http://www.aksci.com/item_detail.php?cat=868269
Acadechem	ACDS-033154	http://www.acadechemical.com/product/107853
Achemo Scientific Limited	AC-16677	http://www.achemo.com/search/?Keyword= 60719-84-8
Achemtek	0104-017105	http://www.achemtek.com/60719-84-8
Alfa Chemistry	AP60719848	https://reagents.alfa-chemistry.com/product/amrinone-cas-60719-84-8-13957.html
Alichem	22004023	http://www.alichem.com/en/products/216151-27-8.html
Allbio Pharm Co., Ltd	AD03248	http://www.allbiopharm.com/product/n/AD03248
Ambinter	Amb18649580	http://www.ambinter.com/reference/18649580
Angel Pharmatech	AG337888	http://www.angelpharmatech.com/60719-84-8.html
Angene	AGN-PC-0JK6MN	http://www.angenechemical.com/productshow/AGN-PC-0JK6MN.html
Anward	ANW-56874	http://www.anward.com/pro_result/43325
Ark Pharm	AK-99994	http://www.arkpharminc.com/products/60719-84-8.html
Aurora Fine Chemicals LLC	A02.558.326	http://online.aurorafinechemicals.com/info?ID=A02.558.326
Aurum Pharmatech LLC	M-2461	http://www.Aurumpharmatech.com/Product/ProductDetails/M_2461
Avantor Inc	101094-302	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-302
Avantor Inc	101096-786	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-786
BLD Pharm	BD12830	http://www.bldpharm.com/products/60719-84-8.html
BioChemPartner	BCP12764	http://www.biochempartner.com/60719-84-8-BCP12764
BioSynth	W-105234	https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/W-105234.html
CSNpharm	CSN10951	https://www.csnpharm.com/products/amrinone.html
Chem Scene	CS-0013064	http://www.chemscene.com/60719-84-8.html
ChemMol	30101988	http://www.chemmol.com/chemmol/30101988.html
ChemMol	49424520	http://www.chemmol.com/chemmol/49424520.html
Chemspace	CSSB00000063426	https://chem-space.com/CSSB00000063426
Clearsynth	CS-T-03714	https://www.clearsynth.com/en/CST03714.html
Combi-Blocks	QA-1160	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-1160
DC Chemicals	DC8957	http://www.dcchemicals.com/product_show-Amrinone.html
Finetech	FT-0601595	http://www.finetechnology-ind.com/prod/detail/pub/60719-84-8.html
Glentham Life Sciences	GP7331	http://www.glentham.com/products/product/GP7331/
Hairui	HR132658	http://www.hairuichem.com/en/product/60719-84-8.html
Lab Network	LN00194482	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00194482
MedChem Express	HY-B1294	https://www.medchemexpress.com/amrinone.html
OChem	822	http://www.ocheminc.com/index.php?act=psearch&pid=719A848
Sigma-Aldrich	A4056_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4056?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1034308_USP	https://www.sigmaaldrich.com/catalog/product/usp/1034308?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017497	http://www.sinfoobiotech.com/product/1020895
Smolecule	S518817	http://www.smolecule.com/products/s518817
THE BioTek	bt-259866	https://www.thebiotek.com/product/inhibitors/bt-259866
eNovation Chemicals	D673798	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673798
eNovation Chemicals	D765978	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765978
eNovation Chemicals	D961064	https://www.enovationchem.com/ProductDetails.asp?ProductID=D961064
mcule	MCULE-2781267039	https://mcule.com/MCULE-2781267039/

PubMed

Title	Date	PubMed
Amrinone for refractory cardiogenic shock following chloroquine poisoning.	1991	1774400
Possible involvement of cyclic adenosine monophosphate-independent mechanism in the positive chronotropic effect of norepinephrine in the isolated guinea pig right atrium.	2001 Aug	11506118
In contrast to forskolin and 3-isobutyl-1-methylxanthine, amrinone stimulates the cardiac voltage-sensitive release mechanism without increasing calcium-induced calcium release.	2001 Sep	11504790
Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts.	2002	12515045
Intraoperative insulin therapy does not reduce the need for inotropic or antiarrhythmic therapy after cardiopulmonary bypass.	2002 Aug	12154416
High-dose amrinone is required to accelerate rewarming from deliberate mild intraoperative hypothermia for neurosurgical procedures.	2002 Jul	12131112
Effects of amrinone on hepatic ischemia-reperfusion injury in rats.	2002 Jul	12076859
[Effects of amrinone in patients undergoing off-pump coronary artery bypass grafting].	2002 May	12058428
Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.	2002 Oct	12356583
[Effect of dexamethasone, aminoguanidin, amrinone on oxygen utilization in endotoxin shock rabbits].	2003 Apr	14754535
Congenital junctional ectopic tachycardia: presentation and outcome.	2003 Jul 1	16943912
Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart.	2003 Jun 6	12665506
Short-term fasting and lipolytic activity in rat adipocytes.	2004 Oct	15523590
Successful allogeneic bone marrow transplantation for acute myelogenous leukemia after drug-induced cardiomyopathy.	2004 Sep	15329467
Meta-analysis of hemodynamic optimization: relationship to methodological quality.	2005	16356226
Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine.	2005 Apr	15892406
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.	2005 Dec 28	16325808
Effect of amrinone on mucosal permeability in experimental intestinal ischaemia/reperfusion injury.	2005 Jul	15972057
The impact of slow rewarming on inotropy, tissue metabolism, and "after drop" of body temperature in pediatric patients.	2005 Jun	16117455
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.	2005 May 9	15910807
Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.	2005 Nov	16236146
Effects of inotropic drugs on mechanical function and oxygen balance in postischemic canine myocardium: comparison of dobutamine, epinephrine, amrinone, and calcium chloride.	2005 Oct	16224144
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.	2006	17096864
Alkaline Phosphatases : Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes.	2006 Jun	18404473
Effect of combining phosphodiesterase III inhibitors with St Thomas Hospital's solution used as transplantation preservative solution in isolated rat hearts.	2006 Jun	16797275
Acute heart failure: inotropic agents and their clinical uses.	2006 Nov	17059376
Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study.	2006 Nov 21	17118183
Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.	2006 Oct 1	16990629
Proper use of phosphodiesterase inhibitors according to the situations.	2006 Sep	17037008
[Current approaches to intraoperative diagnosis and treatment of low cardiac output during cardiosurgical operations].	2006 Sep-Oct	17184052
Investigation of binding proteins for anti-platelet agent K-134 by Drug-Western method.	2007 Feb 23	17207464
Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.	2007 Jan-Feb	17146843
Cirrhotic cardiomyopathy.	2007 Mar 27	17389039
Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria.	2008 Apr	18506213
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.	2008 Jan	18058085
Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute.	2008 Mar	18387066
Drug effect unveils inter-head cooperativity and strain-dependent ADP release in fast skeletal actomyosin.	2009 Aug 21	19520847
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.	2009 Dec	19876734
Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.	2009 Jan	18930951
Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury.	2009 Jan	18468627
Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular control.	2009 Oct 7	19821445
Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control.	2009 Oct 7	19821421

Patents

Sample Use Guides

In Vivo Use Guide

Congestive heart failure IV Initially, 0.75 mg/kg as a slow (over 2–3 minutes) direct injection; if warranted, may administer a supplemental direct IV dose of 0.75 mg/kg 30 minutes after the initial dose.1 60 Direct IV injection is followed by an IV infusion of 5–10 mcg/kg per minute. Duration of therapy determined by clinical response and tolerance to adverse effects.

Route of Administration: Intravenous

In Vitro Use Guide

Inamrinone inhibited human platelet aggregation at 10,800 s(-1) in a dose-dependent manner with the IC(50) value of 61 +/- 8 uM (mean +/- S.D.), Inamrinone significantly inhibited platelet aggregation at 1200 s(-1) only at highest concentration tested (100 uM)

Substance Class	Chemical Created by `admin` on `Thu Jul 06 23:10:03 UTC 2023` Edited by `admin` on `Thu Jul 06 23:10:03 UTC 2023`
Record UNII	JUT23379TN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INAMRINONE

Official Name

English

AMRINONE [MI]

Common Name

English

AMRINONE [JAN]

Common Name

English

5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE

Systematic Name

English

INAMRINONE [USP MONOGRAPH]

Common Name

English

AMRINONE

Official Name

English

AMRINONE [MART.]

Common Name

English

C01CE01

Code

English

INAMRINONE [USAN]

Common Name

English

WINCORAM

Brand Name

English

5-AMINO-3,4'-BIPYRIDYL-6(1H)-ONE

Systematic Name

English

AMRINONE [USP-RS]

Common Name

English

CORDEMCURA

Brand Name

English

NSC-759805

Code

English

VESISTOL

Brand Name

English

WIN-40680

Code

English

Amrinone [WHO-DD]

Common Name

English

INAMRINONE [VANDF]

Common Name

English

WIN 40680

Code

English

INAMRINONE [USP IMPURITY]

Common Name

English

CARTONIC

Brand Name

English

AMRINONE [VANDF]

Common Name

English

AMCORAL

Brand Name

English

(3,4'-BIPYRIDIN)-6(1H)-ONE, 5-AMINO-

Systematic Name

English

amrinone [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC01CE01